Concepedia

Author

Shadia I. Jalal

Indiana University – Purdue University IndianapolisORCID

Also Known As

Einhorn, Lawrence H., Given, Barbara A., Hanna, Nasser, Jalal, Shadia, S. I. Jalal, S. Jalal, S.I. Jalal, Shadia I. Jalal, Shadia I Jalal, Shadia I. Jalal

243

Publications

9.4K

Citations

40

H-Index

96

Concepts

All Affiliations

Indiana University – Purdue University IndianapolisIndiana University School of MedicineIndiana University HealthMerck & Co., Inc., Rahway, NJ, USA (United States)The University of Texas MD Anderson Cancer Center
SI

About

Shadia I. Jalal is an author at Indiana University – Purdue University Indianapolis specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

45

4.3K

2

Health Sciences

11

12

394

3

Engineering

3

3

54

4

Arts

2

2

82

5

Natural Sciences

2

2

68

Shadia I. Jalal

×

71

Publications

6K

Citations

35

H-Index

YearCitations

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei,

The Lancet Oncology

2016

1.4K

Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem,

Journal of the National Comprehensive Cancer Network

2023

450

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín,

Journal of Thoracic Oncology

2019

427

Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma

Toshihiko Doi, Sarina A. Piha‐Paul, Shadia I. Jalal,

Journal of Clinical Oncology

2017

315

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

Yung‐Jue Bang, Yoon‐Koo Kang, Daniel V.T. Catenacci,

Gastric Cancer

2019

242

Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

Hyun Cheol Chung, José A. López-Martín, Stephen Chuan-Hao Kao,

Journal of Clinical Oncology

2018

206

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Hossein Borghaei, Corey J. Langer, Shirish M. Gadgeel,

Journal of Thoracic Oncology

2018

194

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Mark M. Awad, Shirish M. Gadgeel, Hossein Borghaei,

Journal of Thoracic Oncology

2020

175

KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.

Charles S. Fuchs, Toshihiko Doi, Raymond Woo-Jun Jang,

Journal of Clinical Oncology

2017

173

A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179

Greg Andrew Durm, Salma K. Jabbour, Sandra K. Althouse,

Cancer

2020

158

Page 1